Acute Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acute pericarditis is a relatively
common cause of chest pain, with approximately 5% of patients with nonischemic
chest pain being diagnosed with acute pericarditis in the emergency department.
Recurrent or relapsing pericarditis is common, is one of the most challenging
complications of acute pericarditis, and may affect 10–50% of patients. It can
have infectious or non-infectious causes and is characterized by a combination
of signs (e.g., pericarp. dial rubs, electrocardiographic changes, and
pericardial effusion), symptoms (primarily chest pain, but other symptoms such
as dyspnea are possible), and usually elevation of markers of myocardial
inflammation (i.e., protein C reactive). Simultaneous myocardial involvement is
also attributed to about one-third of patients with acute pericarditis, and it
is due to overlapping etiological agents for pericarditis and myocarditis. It
is the first pericarditis attack, generally occurring with an acute onset of
symptoms. It is characterized by chest pain, pericardial friction rub, and
serial ECG changes. Chest pain is the cardinal symptom of pericarditis, usually
precordial or retrosternal, with referral to the trapezius ridge, neck, left
shoulder, or arm.
- Acute Pericarditis incidence cases vary from 325 to 340 per
100,000 population in the USA.
Thelansis’s “Acute Pericarditis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acute
Pericarditis treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acute Pericarditis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Acute Pericarditis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment